Uncovering Pre-targeted Radioimmunotherapy for Novel Radiopharmaceutical Targets
• Sharing early preclinical therapeutic data
• Discussing compassionate use studies for speed to clinic
• Addressing unmet medical need through new targets including, oxMIF, MSLN, HER2, and Fra